Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
29 Gennaio 2024 - 10:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)*
CRISPR Therapeutics AG
(Name of Issuer)
Common
stock
(Title of Class of Securities)
H17182108
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP
No. H17182108 |
13G |
Page 2 of 5 Pages |
1. |
NAMES
OF REPORTING PERSONS |
|
ARK
Investment Management LLC |
|
|
2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
|
(a) ¨ |
|
(b) ¨ |
|
3. |
SEC
USE ONLY |
|
|
|
|
4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION |
|
Delaware,
United States |
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE
VOTING POWER |
|
8,057,147 |
|
|
6. |
SHARED
VOTING POWER |
|
244,377 |
|
|
7. |
SOLE
DISPOSITIVE POWER |
|
8,536,104 |
|
|
8. |
SHARED
DISPOSITIVE POWER |
|
0 |
|
|
9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
8,536,104 |
|
|
10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES |
|
¨ |
|
|
11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
|
10.75% |
|
|
12. |
TYPE
OF REPORTING PERSON |
|
IA |
|
|
CUSIP No. H17182108 |
13G |
Page 3 of 5 Pages |
Item 1(a) Name of issuer:
CRISPR Therapeutics AG
Item 1(b) Address of issuer's principal executive offices:
Baarerstrasse 14
Zug V8 CH-6300
Item 2(a) Name of person filing:
ARK Investment Management LLC
Item 2(b) Address or principal business office or, if none,
residence:
ARK Investment Management LLC
200 Central Avenue
St. Petersburg, FL 33701
Item 2(c) Citizenship:
Delaware, United States
Item 2(d) Title of class of securities:
Common stock
Item 2(e) CUSIP No.:
H17182108
Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) ¨ Broker or dealer registered under section 15 of the Act
(15 U.S.C. 78o);
(b) ¨ Bank as defined in section 3(a)(6) of the Act (15
U.S.C. 78c);
(c) ¨ Insurance company as defined in section 3(a)(19) of the
Act (15 U.S.C. 78c);
(d) ¨ Investment company registered under section 8 of the Investment
Company Act of 1940 (15 U.S.C 80a-8);
(e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f) ¨ An employee benefit plan or endowment fund in accordance
with § 240.13d-1(b)(1)(ii)(F);
(g) ¨ A parent holding company or control person in accordance
with § 240.13d-1(b)(1)(ii)(G);
(h) ¨ A savings associations as defined in Section 3(b) of
the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) ¨ A church plan that is excluded from the definition of
an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
CUSIP No. H17182108 |
13G |
Page 4 of 5 Pages |
Item 4. Ownership
| (a) | Amount beneficially owned: |
8,536,104
10.75%
| (c) | Number of shares as to which such person has: |
| (i) | Sole power to vote or to direct the vote: 8,057,147 |
| (ii) | Shared power to vote or to direct the vote: 244,377 |
| (iii) | Sole power to dispose or to direct the disposition of: 8,536,104 |
| (iv) | Shared power to dispose or to direct the disposition of: 0 |
Item 5. Ownership of 5 Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
To the knowledge of the Reporting Person, no other person has the right
to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents
more than five percent of the number of outstanding class of the shares.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
CUSIP No. H17182108 |
13G |
Page 5 of 5 Pages |
Item 10. Certifications.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in
connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
The reporting persons agree that this statement
is filed on behalf of each of them.
Dated: January 29, 2024
|
ARK Investment Management LLC |
|
|
|
|
By: |
/s/ Kellen Carter |
|
|
Name: Kellen Carter |
|
|
Title: Chief Compliance Officer |
Grafico Azioni CRISPR Therapeutics (NASDAQ:CRSP)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni CRISPR Therapeutics (NASDAQ:CRSP)
Storico
Da Dic 2023 a Dic 2024